People · Operator
Named in public records as an officer, director or promoter · active 2007–2023 · Other Health Care, Other, Other Technology, Medical Devices, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AristaMD, Inc. | — | Other Health Care | Series B | $71.2M | $136.4M | 2020 |
| Foldax, Inc. | — | Other | Series A | $38.7M | $39.4M | 2022 |
| Aventura HQ, Inc. | — | Other Technology | Series A | $34.8M | $19.1M | 2013 |
| Twistle, Inc. | — | Other Health Care | Series B | $21.0M | $405.4M | 2019 |
| Prescient Surgical, Inc. | — | Medical Devices | Series A | $15.6M | $3.5M | 2017 |
| MD Insider, Inc. | — | Other Technology | Series A | $12.8M | $28.4M | 2015 |
| Care Team Connect, Inc. | — | Other Technology | Series A | $9.4M | $55.5M | 2010 |
| Phynd Technologies, Inc. | — | Software / Tech | Series A | $8.9M | $226.6M | 2018 |
| Accenx Technologies, Inc. | — | Other Technology | Seed | $4.6M | $51.1M | 2007 |
| Ascender Software, Inc. | — | Other Technology | Pre-Seed | $865K | $36.6M | 2011 |
Brant Heise at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brant Heise on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eugene Chen | 1 | 9 |
| John Morgan | 1 | 9 |
| Patrick Flynn | 1 | 8 |
| George Wallace | 1 | 8 |
| Scott Huennekens | 1 | 7 |
| Jay Lichter | 1 | 7 |
| Tighe Reardon | 1 | 7 |
| Enrico Picozza | 1 | 7 |
| Robert Coppedge | 1 | 6 |
| Douglas Downs | 1 | 6 |
| John Kuelper | 1 | 6 |
| Thomas Cooper | 1 | 6 |
| Morteza Gharib | 1 | 5 |
| Al Wiegman | 1 | 5 |
| David Norris | 1 | 5 |
| Caleb Winder | 1 | 5 |
| Thomas White | 1 | 5 |
| Craig Cimini | 1 | 5 |
| Joel Krikston | 1 | 4 |
| Peter White | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.